FINWIRES · TerminalLIVE
FINWIRES

Shree Cement's Consolidated Profit Declines in Fiscal Q4

By

-- Shree Cement's (NSE:SHREECEM, BOM:500387) consolidated attributable profit declined to 5.26 billion Indian rupees in the fiscal fourth quarter ended March 31, from 5.74 billion rupees a year ago.

Earnings per share contracted to 145.70 rupees from 159.17 rupees a year earlier, the cement manufacturer said in a filing to the Indian stock exchanges on Wednesday. The EPS was lower than the 148.45 rupees estimated by the analysts polled by Visible Alpha.

Revenue from operations in fiscal Q4, however, increased to 61.0 billion rupees from 55.3 billion rupees a year ago.

The company's board recommended a final dividend of 70 rupees per equity share of 10 rupees each for the financial year 2025-26.

Related Articles

Asia

StarHub's Net Attributable Profit Falls 81% in Q1

StarHub's (SGX:CC3) net attributable profit to shareholders plunged 81% in the first quarter of the year to SG$5.9 million from SG$31.8 million a year earlier, according to a Thursday filing with the Singapore Exchange.Revenue declined 6.1% year over year to SG$507.3 million from SG$540.5 million, mainly due to an across-the-board decline in services revenue.

$SGX:CC3
Asia

Meesho Narrows Consolidated Loss in Fiscal Q4

Meesho (NSE:MEESHO, BOM:544632) narrowed its consolidated attributable loss to 1.66 billion Indian rupees in the fiscal fourth quarter ended March 31, from a loss of 13.9 billion rupees a year ago.Loss per share contracted to 0.36 rupees from a loss per share of 3.39 rupees a year earlier, the online marketplace said in a filing to the Indian stock exchanges on Wednesday. The loss per share was lower than the 0.73 rupees estimated by the analysts polled by Visible Alpha.Revenue from operations in fiscal Q4 increased to 35.3 billion rupees from 24.0 billion rupees a year ago. This is a tad higher than Visible Alpha's estimate of 35.2 billion rupees a year ago.

$BOM:544632$NSE:MEESHO
Asia

Changchun High-Tech Gets Regulatory Nod for Gouty Arthritis Drug

Changchun High-Tech Industry (SHE:000661) subsidiary Changchun Genescience Pharmaceutical obtained China's regulatory approval to manufacture and market its fuxinqibai monoclonal antibody injection.The drug is indicated for acute gouty arthritis attacks in adults poorly responsive to standard therapies, according to a Thursday filing with the Shenzhen bourse.

$SHE:000661